DRUG
Price
$84.66
Change
+$0.39 (+0.46%)
Updated
Dec 24 closing price
Capitalization
671.36M
Intraday BUY SELL Signals
IVA
Price
$4.44
Change
+$0.06 (+1.37%)
Updated
Dec 24 closing price
Capitalization
850.47M
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DRUG vs IVA

Header iconDRUG vs IVA Comparison
Open Charts DRUG vs IVABanner chart's image
Bright Minds Biosciences
Price$84.66
Change+$0.39 (+0.46%)
Volume$117.95K
Capitalization671.36M
Inventiva SA
Price$4.44
Change+$0.06 (+1.37%)
Volume$41.88K
Capitalization850.47M
DRUG vs IVA Comparison Chart in %
DRUG
Daily Signal:
Gain/Loss:
IVA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DRUG vs. IVA commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and IVA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (DRUG: $84.66 vs. IVA: $4.44)
Brand notoriety: DRUG and IVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 68% vs. IVA: 13%
Market capitalization -- DRUG: $671.36M vs. IVA: $850.47M
DRUG [@Biotechnology] is valued at $671.36M. IVA’s [@Biotechnology] market capitalization is $850.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileIVA’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • IVA’s FA Score: 1 green, 4 red.
According to our system of comparison, IVA is a better buy in the long-term than DRUG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 3 TA indicator(s) are bullish while IVA’s TA Score has 4 bullish TA indicator(s).

  • DRUG’s TA Score: 3 bullish, 5 bearish.
  • IVA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, IVA is a better buy in the short-term than DRUG.

Price Growth

DRUG (@Biotechnology) experienced а -3.88% price change this week, while IVA (@Biotechnology) price change was +1.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

IVA is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IVA($850M) has a higher market cap than DRUG($671M). DRUG YTD gains are higher at: 135.036 vs. IVA (107.477).
DRUGIVADRUG / IVA
Capitalization671M850M79%
EBITDA-8.94MN/A-
Gain YTD135.036107.477126%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash51.4MN/A-
Total Debt141KN/A-
TECHNICAL ANALYSIS
Technical Analysis
DRUGIVA
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 7 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
DRUG
Daily Signal:
Gain/Loss:
IVA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFJAX34.460.19
+0.55%
Calvert US Large Cap Value Rspnb Idx A
TNRAX21.600.06
+0.27%
1290 Avantis U.S. Large Cap Growth A
AFGZX29.370.05
+0.17%
Alger Global Equity Z
IEGFX20.970.02
+0.10%
Invesco International Small Company R6
FDCAX46.54N/A
N/A
Fidelity Capital Appreciation

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been closely correlated with HURA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if DRUG jumps, then HURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
+0.46%
HURA - DRUG
69%
Closely correlated
+15.16%
PHMMF - DRUG
42%
Loosely correlated
N/A
IVA - DRUG
41%
Loosely correlated
+1.37%
BIVI - DRUG
40%
Loosely correlated
-3.05%
SYRE - DRUG
37%
Loosely correlated
-0.54%
More

IVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IVA has been loosely correlated with DRUG. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then DRUG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
+1.37%
DRUG - IVA
42%
Loosely correlated
+0.46%
TVGN - IVA
37%
Loosely correlated
+5.55%
OVID - IVA
31%
Poorly correlated
-1.66%
IVF - IVA
30%
Poorly correlated
-1.33%
KURA - IVA
26%
Poorly correlated
+2.50%
More